Drug Trial Radar · NCT02227849
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Aug 2014
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Canagliflozin (TA-7284)Drug
The patients will receive Canagliflozin orally for 52 weeks
GLP-1 analogueDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events)Time frame: 52 Weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Reserch site
Chūbu, Japan
Reserch site
Hokkaido, Japan
Reserch site
Kanto, Japan
Reserch site
Kinki, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.